Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
400 participants
INTERVENTIONAL
2020-01-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Surgical Treatment of Patients With Ischemic Cardiomyopathy
NCT04489355
Surgical Treatment of Ischemic Mitral Regurgitation
NCT01368575
Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.
NCT02054221
Mitral Valve in Hypertrophic Cardiomyopathy
NCT03877731
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
NCT04470102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IMR study hypothesis: Stress echocardiography data, including ERO, RV, pulmonary pressure (PA) pressure, beta-lines - B-lines, contractile reserve, could be indications for mitral valve intervention in patient with CAD and chronic secondary mitral regurgitation, undergoing CABG. The patients of the group with non-massive (ERO-0.2 cm2 and RV-30ml) IMR have positive effect by mitral surgery if they have increasing IMR during exercise test. The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with non-massive non-operated subgroup.
Aim: To assess the value of stress echo testing for ischemic mitral surgery indication in patients undergoing CABG.
Inclusion criteria for all projects are:
1. Age \> 18 years
2. IMR, ERO≥0.2 cm2 and RV≥30 ml.
3. Indication for CABG
Exclusion criteria for all projects are:
1. Unwillingness to give informed consent and to enter a regular follow-up program.
2. Contraindications for stress echo.
Methods and design:
1. In a prospective multicenter international randomized study, we will recruit patients whom CABG is planned.
2. Conventional transthoracic echo. Patients will include into two groups:
Group 1 - "Non-massive IMR" - ERO-0.2-0.39 cm2, and RV-30-59ml. Group 2 - "Massive IMR" - ERO≥0.4 cm2 and RV≥60 ml.
3. Randomization of Group 1 (surgery/non-surgery).
4. Exercise stress echocardiography of all the patients (Group 1 and Group 2). regional wall motion abnormality (RWMA), ejection fraction (EF), end diastolic volume (EDV), end systolic volume (ESV), contractile reserve, B-lines, ERO, RV, PA pressure at rest and during stress.
5. 1-year clinical outcomes
6. 1-year transthoracic echo data.
7. 1-year stress echocardiography data.
8. 3-year clinical outcomes
9. 3-year transthoracic echo data.
10. 3-year stress echocardiography data. Primary end-points: death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema (MACE).
Secondary end-points: physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data.
Expected results. Group 1, CABG - subgroup, CABG+mitral surgery subgroup. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data in CABG+mitral surgery subgroup already in 1-year follow-up. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echo), EDV, left atrium volume, EF at rest and during stress echo, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with CABG-subgroup already in 1-year follow-up. It's expected that more pronounce changes will be in CABG+mitral surgery subgroup with previously increasing IMR. The worst results are expected in CABG-subgroup with previously increasing IMR during exercise. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc). We expected reduced MACE till 3 year in CABG+mitral surgery subgroup with increasing IMR in comparison with CABG-subgroup with increasing IMR.
Group 2, The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with CABG-subgroup with increasing IMR from group 1. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CABG/increasing MR
non-massive IMR with increasing IMR during exercise - CABG only
No interventions assigned to this group
CABG+mitral surgery (MS)/increasing MR
non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
Mitral surgery
Guidelines approved mitral surgery
CABG/non-increasing MR
non-massive IMR non-increasing IMR during exercise - CABG only
No interventions assigned to this group
CABG+MS/non-increasing MR
non-massive IMR non-increasing IMR - CABG+ mitral surgery
Mitral surgery
Guidelines approved mitral surgery
Control 1
massive IMR at rest without increasing during exercise - CABG+ mitral surgery
Mitral surgery
Guidelines approved mitral surgery
Control 2
massive IMR at rest with increasing during exercise - CABG+ mitral surgery
Mitral surgery
Guidelines approved mitral surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitral surgery
Guidelines approved mitral surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for CABG
Exclusion Criteria
* Contraindications for SE.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saint Petersburg State University, Russia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Efremov Sergey
Deputy director for science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dmitry Shmatov, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Saint Petersburg State University, Russia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Petersburg State University
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.